Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens

Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens

We have developed a single process for producing two key COVID-19 vaccine antigens: SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are featured in various COVID-19 vaccine formats, including SOBERANA 01 and the licensed SOBERANA 02, and SOBERANA Plus. Our approach involve...

Full description

Bibliographic Details
Main Authors: Tammy Boggiano-Ayo, Julio Palacios-Oliva, Sumlai Lozada-Chang, Ernesto Relova-Hernandez, Jose Gomez-Perez, Gonzalo Oliva, Lourdes Hernandez, Alexi Bueno-Soler, Daidee Montes de Oca, Osvaldo Mora, Roberto Machado-Santisteban, Dayana Perez-Martinez, Beatriz Perez-Masson, Yanelys Cabrera Infante, Lisandra Calzadilla-Rosado, Yaima Ramirez, Judey Aymed-Garcia, Ingrid Ruiz-Ramirez, Yamile Romero, Tania Gomez, Luis A. Espinosa, Luis Javier Gonzalez, Annia Cabrales, Osmany Guirola, Kathya Rashida de la Luz, Franciscary Pi-Estopiñan, Belinda Sanchez-Ramirez, Dagmar Garcia-Rivera, Yuri Valdes-Balbin, Gertrudis Rojas, Kalet Leon-Monzon, Eduardo Ojito-Magaz, Eugenio Hardy
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
SARS-CoV-2
RBD
CHO cells
perfusion culture
COVID-19
vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fbioe.2023.1287551/full

Internet

https://www.frontiersin.org/articles/10.3389/fbioe.2023.1287551/full

Similar Items